Global Amyotrophic Lateral Sclerosis Treatment Market Size

Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis

The amyotrophic lateral sclerosis treatment market is expected to register a CAGR of 6.3% during the forecast period (2022-2027).

COVID-19 had a significant impact on the studied market as it affected not only diagnostic and treatment procedures but also research and development activities in the area. For instance, in June 2020, the World Health Organization issued the results of a survey conducted in 155 countries for three weeks in May 2020, which showed that the prevention and treatment services of various chronic diseases, including various neurodegenerative disorders, had been severely disrupted, and this has become a significant concern because people living with chronic disorders were at higher risk of severe COVID-19-related illness and death. Therefore, COVID-19 harmed the studied market.

In addition, the rising prevalence of amyotrophic lateral sclerosis and the growing geriatric population are actively affecting the growth of the studied market.

According to the United Nations World Population Prospects 2022 report, there are 77.1 million people aged 65 years or over living in the world in 2022, and this number is projected to reach 1.6 billion by the year 2050. This surge in the geriatric population is expected to increase the burden of rare neurological diseases which is likely to augment the growth of the studied market over the forecast period.

Furthermore, the article titled "Estimated Prevalence and Incidence of Amyotrophic Lateral Sclerosis and SOD1 and C9orf72 Genetic Variants" published in Neuroepidemiology Journal in July 2021 stated that combined prevalence rates (per 100,000 people) and incidence rates (per 100,000 person-years) were 6.22 and 2.31 for Europe, 5.20 and 2.35 for North America, 3.41 and 1.25 for Latin America, 3.01 and 0.93 for Asian countries excluding Japan, and 7.96 and 1.76 for Japan, respectively. The increase in prevalence and incidence of the disease is expected to increase the demand for the treatment and thus boost the market growth.

The advancements and increasing product approvals, along with partnerships and collaborations by key players are helping in the market growth. For instance, in June 2021, CRISPR Therapeutics and CapsidaBiotherapeutics Inc. entered into a strategic partnership to research, develop, manufacture and commercialize in vivo gene editing therapies using CRISPR technology delivered with engineered AAV vectors for the treatment of familial amyotrophic lateral sclerosis (ALS) and Friedreich's ataxia. Such partnerships are likely to bolster market growth.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period. However, the high cost of treatment is likely to impede market growth.